Vaxcyte price target raised to $89 from $85 at BTIG

BTIG raised the firm’s price target on Vaxcyte (PCVX) to $89 from $85 and keeps a Buy rating on the shares after its Q4 results. The details have led to a noisy 12 months for the Vaxcyte stock, but the very significant advantage of VAX-31 over the remainder of the PCV field seems likely to leave the vaccine with the best overall profile for both adults and children, the analyst tells investors in a research note.